UK biotech Cytospire Therapeutics has closed a £61m Series A round to advance its development of antibodies used in cancer treatment.
Cytospire is developing a portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of immune cells.
In addition to advancing its development capabilities, the funding will be used to support a clinical study to evaluate its lead programme, CYT X300, as a treatment for EGFR-positive solid tumours, such as colorectal, head and neck and non-small cell lung cancers.
The round was led by 4BIO Capital, with investment from new syndicate members Servier Ventures, Sound Bioventures and Criteria Bio Ventures, as well as from existing investors Abingworth and LifeArc Ventures.
Modi Ventures, Medical Incubator Japan and Pathway Bioventures also joined the round as new investors, and the British Business Bank invested £12m.
“Cancer immunotherapy has provided a step-change in treatment for many types of cancer over the past decade, but we need to do more,” says Owen Smith, partner at 4BIO Capital and board member at Cytospire.
“We are proud to have led the Series A alongside this strong investor syndicate. It is exciting to see the company advance CYT X300 and its pioneering portfolio of cancer therapies into the clinic to improve outcomes for cancer patients.”
